IMMURON LTD宣布已制定关键战略方针,将通过寻求外部合作的方式为旗下两款核心产品——Travelan与IMM-529的临床研究计划注入资金动力。该决策旨在加速推进两项临床项目的研发进程,同时优化公司资源分配结构。
IMMURON LTD宣布已制定关键战略方针,将通过寻求外部合作的方式为旗下两款核心产品——Travelan与IMM-529的临床研究计划注入资金动力。该决策旨在加速推进两项临床项目的研发进程,同时优化公司资源分配结构。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.